Compounds > zidovudine
Page last updated: 2024-08-23

zidovudine and alendronate

zidovudine has been researched along with alendronate in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Kilby, M; McDonald, JM; Pan, G1
Goltz, D; Jauch, C; Schott, H; Schott, TC; Schwendener, RA1

Reviews

1 review(s) available for zidovudine and alendronate

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for zidovudine and alendronate

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors.
    AIDS research and human retroviruses, 2006, Volume: 22, Issue:11

    Topics: Alendronate; Animals; Apoptosis; Cell Differentiation; Didanosine; Humans; Leukocytes, Mononuclear; Male; Mice; Mice, Inbred C57BL; Osteoclasts; Osteoprotegerin; RANK Ligand; Reverse Transcriptase Inhibitors; Zidovudine

2006
N⁴-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate).
    Bioorganic & medicinal chemistry, 2011, Jun-01, Volume: 19, Issue:11

    Topics: Alendronate; Animals; Antimetabolites, Antineoplastic; Arabinofuranosyluracil; Bone and Bones; Bone Density Conservation Agents; Cell Line, Tumor; Cytidine; Diphosphonates; Drug Screening Assays, Antitumor; Durapatite; Fluorouracil; Humans; Macrophages; Mice; Pamidronate; Uridine; Zidovudine

2011